Fly Labs
Ask FlyBot

Cheaper ADHD diagnosis without expensive telehealth

GPs are unwilling to diagnose ADHD, forcing people to use telehealth clinics that charge around $1000 for quick online questionnaires primarily to get stimulant prescriptions. User explicitly seeks a cheaper alternative.

XToolMedicine & HealthSource
0Sign in to voteCopy link

FL score

62

out of 100

Verdict

VALIDATE

medium confidence

Competition

No competitor data yet

Trend

No signal yet

Reduce ADHD diagnosis costs from $1000 to $200-300 by creating a structured assessment tool that GPs can use confidently in their existing practices.

The pain

People with suspected ADHD face a choice: wait months for reluctant GPs or pay $1000+ to telehealth clinics for a 30-minute questionnaire and prescription. The telehealth model exploits diagnosis gatekeeping and patient desperation. GPs avoid ADHD diagnosis due to liability concerns, lack of confidence in assessment, and time constraints.

The gap

No affordable, credible middle ground exists. GPs need a tool that reduces their diagnostic liability and gives them confidence. Patients need a path that costs 80% less than telehealth but feels legitimate enough that GPs will act on it.

Build angle

Create a clinical-grade ADHD assessment platform (questionnaires, attention tests, history forms) that generates a report GPs can use to justify diagnosis and prescribing. Position it as a tool FOR GPs, not around them. Charge $200-300 per assessment. Revenue comes from patients, but the product is designed to make GPs' jobs easier and safer.

Strengths

  • Clear, quantifiable pain point with real pricing data ($1000 vs. $200)
  • Large addressable market (estimated 10M undiagnosed adults in US alone)
  • Regulatory pathway exists (clinical decision support tools have lighter oversight than diagnostic devices)
  • Solves a real GP problem (confidence + liability reduction), not just patient demand
  • Defensible economics: 70%+ gross margins on digital assessment

Risks

  • Regulatory uncertainty: FDA may classify this as a medical device requiring 510(k) clearance, adding 18-24 months and $500k+
  • GP adoption is the real bottleneck, not patient demand. Doctors may ignore your tool if they're already uncomfortable with ADHD diagnosis
  • Telehealth clinics have no incentive to use you and will compete aggressively on price if threatened
  • Liability exposure: if someone is misdiagnosed using your tool, you could face lawsuits even if you disclaim responsibility
  • Insurance reimbursement unclear: patients may not pay out-of-pocket if they think insurance should cover it
  • You're still operating in a gatekeeping system. A better long-term solution is changing GP incentives or regulations, which you can't control

Questions about this idea?

FlyBot reads the scoring and gives you a second opinion on “Cheaper ADHD diagnosis without expensive telehealth”.

Open FlyBot